行情

ALIM

ALIM

Alimera医疗科学
NASDAQ

实时行情|Nasdaq Last Sale

0.3592
-0.0042
-1.14%
已收盘, 16:00 10/17 EDT
开盘
0.3706
昨收
0.3633
最高
0.3879
最低
0.3400
成交量
13.71万
成交额
--
52周最高
1.210
52周最低
0.3210
市值
2,550.30万
市盈率(TTM)
0.9562
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALIM 新闻

  • Alimera Reports Marketing Authorization for ILUVIEN In Portugal For Treatment Of Non-Infectious Posterior Uveitis
  • Benzinga.10/03 12:41
  • Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis
  • GlobeNewswire.10/03 12:30
  • Alimera Sees Prelim. Q3 Sales Exceeding $12.8M
  • Benzinga.10/02 12:06
  • Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019
  • GlobeNewswire.10/02 12:00

更多

所属板块

制药
+0.54%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

ALIM 简况

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
展开

Webull提供Alimera Sciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。